Holen Sie sich die Stockscreener-App
2.15
11.32%
-0.28
Schlusskurs vom Vortag:
$2.43
Offen:
$2.43
24-Stunden-Volumen:
53,023
Relative Volume:
0.22
Marktkapitalisierung:
$7.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.11M
KGV:
-0.2006
EPS:
-10.7181
Netto-Cashflow:
$-13.60M
1W Leistung:
-17.43%
1M Leistung:
-6.71%
6M Leistung:
-1.15%
1J Leistung:
-60.11%
1-Tages-Spanne:
$2.12
$2.43
1-Wochen-Bereich:
$2.1387
$2.68
52-Wochen-Spanne:
$1.6701
$14.24
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Firmenname
Processa Pharmaceuticals Inc
Sektor
Branche
Telefon
443-776-3133
Adresse
601 21ST STREET, SUITE 300, VERO BEACH
Compare PCSA vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
2.135 | 8.15M | 0 | -14.11M | -13.60M | -10.72 |
VRTX
Vertex Pharmaceuticals Inc
|
515.47 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.53 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.02 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.46 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-25 | Eingeleitet | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Aktie (PCSA) Neueste Nachrichten
Processa Pharmaceuticals 3Q 2026: Net loss $(3.27M), EPS $(1.19) — 10-Q Summary - TradingView
Processa Pharmaceuticals (NASDAQ: PCSA) lands $183M funding and Vidya BTK acquisition - Stock Titan
Form 8K Processa Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting - Investing.com
Processa Pharmaceuticals Inc (PCSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 8K Processa Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals shareholders approve incentive plan amendment and board elections - Investing.com Nigeria
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Share Price, PCSA Stock News, PCSA Share Price & Updates - Kalkine
Processa Pharmaceuticals Inc (PCSA) Stock News Today - TradingKey
Processa Pharmaceuticals, Inc. 8-K SEC Filing Details – Nasdaq Listed Company Information (July 30, 2026) - Minichart
Processa Pharmaceuticals Shareholders Approve Key Governance Changes - TipRanks
Processa Pharmaceuticals (NASDAQ: PCSA) adds 200,000 incentive shares - Stock Titan
Mintz Advises on $200 Million Private Placement Concurrent with Vidya Therapeutics’ and Processa Pharmaceuticals’ Merger Transaction - Mintz
Processa Pharmaceuticals Inc (PCSA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Processa acquires Vidya and its BTK inhibitor - The Pharma Letter
Processa Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding from a group of investors - marketscreener.com
Processa Merges With Vidya and Secures $200 Million PIPE; Terminates Elion License - TradingView
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREA - GlobeNewswire
Processa Pharmaceuticals Inc - TradingKey
Form 4 Processa Pharmaceuticals Inc For: 28 July By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals (PCSA) grants director 33,500 RSUs and reports option stake - Stock Titan
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer SKIBSTED RUSSELL - Moomoo
Processa Pharmaceuticals Inc (PCSA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PCSA|Processa Pharmaceuticals Inc|Price:2.490|Chg%:-0.010 - TradingKey
PCSA|Processa Pharmaceuticals Inc|Price:2.605|Chg%:+0.005 - TradingKey
Processa Pharma Market Sentiment - Benzinga España
Processa Pharmaceuticals Inc (PCSA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Processa Pharmaceuticals Inc (PCSA) Income Statement - TradingKey
Processa Pharmaceuticals Inc (PCSA) Balance Sheet - TradingKey
PCSA|Processa Pharmaceuticals Inc|Price:2.600|Chg%:-0.270 - TradingKey
PCSA Q4 2025 Earnings: Deeper Loss Per Share Yet Stock Rises 4.2% – Investor Focus Shifts to Pipeline ProgressTax Rate Impact - dars.gov.et
Processa Pharmaceuticals Inc. (PCSA) Q4 2025 Earnings: EPS Misses Estimates, No Revenue ReportedOperating Margin Analysis - dars.gov.et
Processa Pharmaceuticals Q4 2025 Earnings: EPS Miss Drives Stock Surge – Investor Focus Shifts to Pipeline - dars.gov.et
Processa Pharma (PCSA) Stock Analysis Report | Financials & Insights - Benzinga España
Insider Buying: Russell Skibsted Acquires Additional Shares of P - GuruFocus
Processa Pharmaceuticals CEO George Ng acquires $5,900 in stock - Investing.com
Processa Pharmaceuticals CEO George Ng acquires $5,900 in stock By Investing.com - Investing.com South Africa
Form 4 Processa Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
Insider purchase: Processa (NASDAQ: PCSA) CAO adds 2,436 shares in open-market buy - Stock Titan
Processa (PCSA) strategy chief adds 2,106 shares in insider buy - Stock Titan
Processa Pharmaceuticals (PCSA) CEO adds 3,057 shares in open-market buy - Stock Titan
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Ng George K - Moomoo
CFO of Processa (NASDAQ: PCSA) adds 3,277 shares in open-market buy - Stock Titan
Processa Pharmaceuticals (PCSA) director buys 2,531 shares in open market - Stock Titan
Processa Pharmaceuticals, Inc. Financial Disclosures & SEC Filings - TradingView
Form 4 Processa Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Canada
Processa (NASDAQ: PCSA) director Yorke vests 203-share restricted stock award - Stock Titan
[Form 4] Processa Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Processa Pharmaceuticals (PCSA) director receives 203 shares from vesting - Stock Titan
Processa Pharmaceuticals (PCSA) director gets 203 shares from service award - Stock Titan
PCSA Q4 2025 Earnings: Wider-Than-Expected EPS Loss Amid Pipeline DevelopmentAnnual Report - dars.gov.et
Finanzdaten der Processa Pharmaceuticals Inc-Aktie (PCSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Processa Pharmaceuticals Inc-Aktie (PCSA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lin Patrick | Chief Business - Strategy Off |
Jun 30 '26 |
Buy |
1.93 |
2,106 |
4,065 |
13,113 |
| Ng George K | Chief Executive Officer |
Jul 01 '26 |
Buy |
1.93 |
3,057 |
5,900 |
15,492 |
| SKIBSTED RUSSELL | Chief Financial Officer |
Jun 30 '26 |
Buy |
1.93 |
3,277 |
6,325 |
16,689 |
| Young David | Pres. Research & Development |
Jun 30 '26 |
Buy |
1.93 |
2,531 |
4,885 |
21,729 |
| Young David | Pres. Research & Development |
Jun 15 '26 |
Buy |
2.22 |
2,067 |
4,589 |
19,198 |
| SKIBSTED RUSSELL | Chief Financial Officer |
Jun 15 '26 |
Buy |
2.22 |
2,654 |
5,892 |
13,412 |
| Ng George K | Chief Executive Officer |
Jun 15 '26 |
Buy |
2.22 |
2,465 |
5,472 |
12,435 |
| Lin Patrick | Chief Business - Strategy Off |
Jun 15 '26 |
Buy |
2.22 |
1,831 |
4,065 |
11,007 |
| Guy Wendy | Chief Administrative Officer |
Jun 15 '26 |
Buy |
2.22 |
2,118 |
4,702 |
11,958 |
| Young David | Pres. Research & Development |
May 29 '26 |
Buy |
2.57 |
1,786 |
4,590 |
17,131 |
2.67%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):